These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30791936)

  • 1. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Cao W; Li J; Hao Q; Vadgama JV; Wu Y
    Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer.
    Zhao Z; Li L; Du P; Ma L; Zhang W; Zheng L; Lan B; Zhang B; Ma F; Xu B; Zhan Q; Song Y
    Theranostics; 2019; 9(5):1401-1416. PubMed ID: 30867840
    [No Abstract]   [Full Text] [Related]  

  • 3. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demethoxycurcumin inhibits energy metabolic and oncogenic signaling pathways through AMPK activation in triple-negative breast cancer cells.
    Shieh JM; Chen YC; Lin YC; Lin JN; Chen WC; Chen YY; Ho CT; Way TD
    J Agric Food Chem; 2013 Jul; 61(26):6366-75. PubMed ID: 23777448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
    Zhang HP; Jiang RY; Zhu JY; Sun KN; Huang Y; Zhou HH; Zheng YB; Wang XJ
    Breast Cancer; 2024 Jul; 31(4):539-551. PubMed ID: 38630392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
    Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
    PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator.
    Lee KH; Hsu EC; Guh JH; Yang HC; Wang D; Kulp SK; Shapiro CL; Chen CS
    J Biol Chem; 2011 Nov; 286(45):39247-58. PubMed ID: 21917926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple negative breast cancer: special histological types and emerging therapeutic methods.
    Cao L; Niu Y
    Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
    James N; Owusu E; Rivera G; Bandyopadhyay D
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of AMPK and Akt in triple negative breast cancer lung colonization.
    Johnson J; Chow Z; Lee E; Weiss HL; Evers BM; Rychahou P
    Neoplasia; 2021 Apr; 23(4):429-438. PubMed ID: 33839456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation.
    Gollavilli PN; Kanugula AK; Koyyada R; Karnewar S; Neeli PK; Kotamraju S
    FEBS J; 2015 Oct; 282(20):3971-85. PubMed ID: 26236947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xianlinglianxiafang Inhibited the growth and metastasis of triple-negative breast cancer via activating PPARγ/AMPK signaling pathway.
    Yang X; Yang R; Zhang Y; Shi Y; Ma M; Li F; Xie Y; Han X; Liu S
    Biomed Pharmacother; 2023 Sep; 165():115164. PubMed ID: 37478577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VSP‑17 suppresses the migration and invasion of triple‑negative breast cancer cells through inhibition of the EMT process via the PPARγ/AMPK signaling pathway.
    Xu X; Liu M; Yang Y; Wei C; Zhang X; Song H; Wang Y; Duan X
    Oncol Rep; 2021 Mar; 45(3):975-986. PubMed ID: 33650675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
    Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
    Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
    Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
    Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.